Related Experiment Video

Updated: May 24, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

CXCR4 inhibitors: tumor vasculature and therapeutic challenges

Filomena de Nigris1, Concetta Schiano, Teresa Infante

  • 1Department of General Pathology and Excellence Research Centre on Cardiovascular Diseases, 1st School of Medicine, Second University of Naples, Complesso S. Andrea delle Dame, Via Costantinopoli 16, Naples, 80138, Italy.

Recent Patents on Anti-Cancer Drug Discovery
|March 2, 2012
PubMed

Insights

Blocking the CXCL12/CXCR4 pathway shows promise for cancer treatment. Targeting this axis, particularly with agents like Plerixaform, may prevent tumor recurrence and aid neo-adjuvant therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • CXCL12 (SDF-1) is a key ligand for CXCR4 and CXCR7 receptors.
  • CXCL12 promotes tumor angiogenesis and metastasis in CXCR4-expressing cancers.
  • Elevated CXCL12 post-therapy can drive tumor recurrence.

Purpose of the Study:

  • To review patent applications and clinical data on targeting the CXCL12/CXCR4 axis for cancer treatment.
  • To assess the potential of anti-CXCR4 agents in neo-adjuvant and adjuvant cancer therapies.

Main Methods:

  • Review of patent applications (2008-2011) related to tumor angiogenesis.
  • Analysis of clinical trial data for anti-CXCR4 agents.
  • Consideration of alternative strategies like RNA interference and miRNA.

Main Results:

  • AMD3100 (Plerixaform) is approved for stem cell mobilization.
  • Several anti-CXCR4 agents (BKT140, POL6326, TG-0054, Nox-A12, MSX-122) are in clinical trials for various cancers.
  • CXCR7 inhibitors (CCX2066) are in preclinical development.

Conclusions:

  • The CXCL12/CXCR4 axis is a viable therapeutic target for cancer.
  • Anti-CXCR4 agents show potential as neo-adjuvant and adjuvant therapies, alone or in combination.
  • Further research into RNA interference and miRNA strategies is warranted for solid tumor treatment.

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...